Jonathan Digby‐Bell

The share of this author’s assessed papers carrying a ⚑ flag. A concentration is a prompt for expert review — never, on its own, a determination about the person.

Collaborators, sized by shared output and coloured by their own reproducibility (green = high, red = low). Click a node to open their card. A pattern is a prompt for review, never a determination.

How this author’s assessed papers reproduced — the outcome of reproduction attempts, not a judgement of the person. Coverage is partial and grows over time.

Assessed papers (1)

• Genetics of circulating inflammatory proteins identifies drivers of immune-mediated disease risk and therapeutic targets.
  2023 L1 93/100

1 assessed by us (1 reproduced) · 37 not yet assessed — every PubMed paper on record, linked below.

• Janus Kinase Inhibitor-Induced Acne in Inflammatory Bowel Disease: An International, Multicenter, Retrospective Cohort Study ↗

  Clinical Gastroenterology and Hepatology · 2025 · PMID 40505791
  not yet assessed
• P0356 A case of pulmonary nodules in Ulcerative Colitis and primary sclerosing cholangitis: is it drug or disease? ↗

  Journal of Crohn s and Colitis · 2025
  not yet assessed
• Genetics of circulating inflammatory proteins identifies drivers of immune-mediated disease risk and therapeutic targets

  Nature Immunology · 2023 · PMID 37563310
  L1 93/100
• Author Correction: Genetics of circulating inflammatory proteins identifies drivers of immune-mediated disease risk and therapeutic targets ↗

  Nature Immunology · 2023 · PMID 37679551
  not yet assessed
• Mapping pQTLs of circulating inflammatory proteins identifies drivers of immune-related disease risk and novel therapeutic targets ↗

  medRxiv · 2023
  not yet assessed
• Interleukin-22 regulates neutrophil recruitment in ulcerative colitis and is associated with resistance to ustekinumab therapy ↗

  Nature Communications · 2022 · PMID 36192482
  not yet assessed
• 792: MICROBIOTA-RESPONSIVE CYTOTOXIC, POLYFUNCTIONAL CD4+ T CELLS ARE ENRICHED IN ULCERATIVE COLITIS AND ARE ASSOCIATED WITH RESISTANCE TO ANTI-CYTOKINE THERAPIES ↗

  Gastroenterology · 2022
  not yet assessed
• The Reliability and Accuracy of Endoscopic Items and Scores Used in the Assessment of the Ileoanal Pouch and Cuff ↗

  Journal of Crohn s and Colitis · 2021 · PMID 34302731
  not yet assessed
• P594 Utilisation of anti-TNF agents in phlegmonous Crohn’s disease: an Australian tertiary referral centre experience ↗

  Journal of Crohn s and Colitis · 2021
  not yet assessed
• Editorial: balancing safety and efficacy—6‐TGN thresholds in NUDT15 intermediate metabolisers treated with thiopurines ↗

  Alimentary Pharmacology & Therapeutics · 2020 · PMID 32656842
  not yet assessed
• Checkpoint Inhibitor Induced Colitis is Dependent on the Microbiota and Activation of Cytotoxic Innate and Adaptive Lymphocytes ↗

  SSRN Electronic Journal · 2020
  not yet assessed
• Interleukin-22 orchestrates a pathological endoplasmic reticulum stress response transcriptional programme in colonic epithelial cells ↗

  Gut · 2019 · PMID 31792136
  not yet assessed
• Interrogating host immunity to predict treatment response in inflammatory bowel disease ↗

  Nature Reviews Gastroenterology & Hepatology · 2019 · PMID 31767987
  not yet assessed
• DOP06 Dynamic shifts in the balance of gut homing Treg and Th17 cells play a critical role in ulcerative colitis and may predict response to vedolizumab therapy ↗

  Journal of Crohn s and Colitis · 2019
  not yet assessed
• DOP60 The interleukin 22 transcriptional programme is activated in human colonic inflammation and associated to anti-TNFα primary non-response in Crohn’s ↗

  Journal of Crohn s and Colitis · 2019
  not yet assessed
• P083 The transcriptomic signature of IL-23-treated lamina propria mononuclear cells is significantly enriched for genes in the Th17 pathway and is enriched in active UC ↗

  Journal of Crohn s and Colitis · 2019
  not yet assessed
• Comparison of Different Strategies for Providing Fecal Microbiota Transplantation to Treat Patients with Recurrent Clostridium difficile Infection in Two English Hospitals: A Review ↗

  Infectious Diseases and Therapy · 2018 · PMID 29450831
  not yet assessed
• PWE-022 Gut-homing TH17 cells are selectively targeted by vedolizumab and may predict clinical response in IBD ↗

  2018
  not yet assessed
• Successful faecal microbiota transplant for recurrent Clostridium difficile infection delivered by colonoscopy through a diverted ileostomy in a patient with severe perianal Crohn’s disease ↗

  BMJ Case Reports · 2018 · PMID 29507020
  not yet assessed
• OTU-030 Faecal microbiota transplantation for recurrent clostridium difficile infection: real world uk data ↗

  2018
  not yet assessed
• DOP075 Colonic gamma delta t-cells respond innately to NKG2D ligands and are grossly dysregulated in active inflammatory bowel disease ↗

  Journal of Crohn s and Colitis · 2018
  not yet assessed
• Tu1811 - Colonic Gamma Delta T Cells Respond Innately to Nkg2D Ligands and are Grossly Dysregulated in Active Inflammatory Bowel Disease ↗

  Gastroenterology · 2018
  not yet assessed
• PWE-015 Clinical efficacy and safety of anti-TNF therapy in inflammatory bowel disease in the elderly ↗

  2018
  not yet assessed
• Golimumab: early experience and medium-term outcomes from two UK tertiary IBD centres ↗

  Frontline Gastroenterology · 2017
  not yet assessed
• Uvular necrosis following diagnostic gastroscopy ↗

  BMJ Case Reports · 2017 · PMID 29269361
  not yet assessed
• PTH-114 Dedicated endoscopic ibd surveillance list improves adherence to guidelines ↗

  2017
  not yet assessed
• CLINICAL EFFICACY AND SAFETY OF ANTI-TNF THERAPY IN INFLAMMATORY BOWEL DISEASE IN THE ELDERLY: A UK TERTIARY REFERRAL CENTRE EXPERIENCE ↗

  2017
  not yet assessed
• Vedolizumab: early experience and medium-term outcomes from two UK tertiary IBD centres ↗

  Frontline Gastroenterology · 2016 · PMID 28839909
  not yet assessed
• Utilisation of anti-TNF levels in a UK tertiary IBD centre ↗

  Frontline Gastroenterology · 2016 · PMID 28839908
  not yet assessed
• Sa1972 Factors Influencing Infliximab and Adalimumab Antibody Formation and 6 Month Retrospective Follow up in a Tertiary IBD Centre ↗

  Gastroenterology · 2016
  not yet assessed
• PTU-062 Vedolizumab: Early Experience and Medium-Term Follow up Data from Two UK Tertiary IBD Centres ↗

  2016
  not yet assessed
• PTH-053 Factors Influencing Infliximab and Adalimumab Antibody Formation and 6 Month Retrospective Follow-Up in A Tertiary IBD Centre ↗

  2016
  not yet assessed
• Prolonged-release budesonide for mild-to-moderate ulcerative colitis ↗

  Prescriber · 2015
  not yet assessed
• Fragility fracture risk in cirrhosis: a comparison of the fracture risk assessment tool, British Society of Gastroenterology and National Institute for Health and Clinical Excellence guidelines ↗

  Frontline Gastroenterology · 2012 · PMID 28839671
  not yet assessed
• P25 Fragility fracture risk in cirrhosis: a comparison of the fracture risk assessment tool (FRAX_), BSG and NICE guidelines ↗

  Gut · 2011
  not yet assessed
• Lived to tell ↗

  BMJ · 2005
  not yet assessed
• VEGF165b, an Inhibitory Vascular Endothelial Growth Factor Splice Variant ↗

  Cancer Research · 2004 · PMID 15520188
  not yet assessed
• PC31 EXPRESSION OF THE INHIBITORY VEGF ISOFORM VEGF 165b IN HUMAN KIDNEY ↗

  Microcirculation · 2004
  not yet assessed